DJIA 17,164.95 -251.90 -1.45%
NASDAQ 4,635.24 -48.17 -1.03%
S&P 500 1,994.99 -26.26 -1.30%
market minute promo

Exelixis (NASDAQ: EXEL)

1.87 -0.10 (-5.08%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

EXEL $1.87 -5.08%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $1.95
Previous Close $1.97
Daily Range $1.81 - $1.97
52-Week Range $1.26 - $7.58
Market Cap $365.1M
P/E Ratio -1.34
Dividend (Yield) $0.00 (0.0%)
Volume 3,252,161
Average Daily Volume 3,287,412
Current FY EPS -$1.41

Sector

Healthcare

Industry

Drugs

Exelixis (EXEL) Description

A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. Website: http://www.exelixis.com/

News & Commentary Rss Feed

Why Shares of Exelixis, Inc. Surged

The cancer-specialist biotech company may be benefiting from a lack of bad news.

Exelixis (EXEL) Flagged As Strong On High Volume

This Popular Beverage Could Be Responsible For a 20% Reduction in Melanoma Risk

The good news: this beverage reduced the risk of an aggressive form of skin cancer by 20% in a very large study. The better news: 83% of you are already consuming this beverage on a daily basis!

Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 4

The Surprising Thing Most of 2014's Top 10 Stocks Have in Common

8 out of 10 of last year's best-performing stocks have this one important common denominator.

Exelixis (EXEL) Is Today's Strong On High Volume Stock

Update: My Take On Exelixis' New Agreement With Sobi To Provide COMETRIQ In Europe

3 Biotech Stocks That Could Trounce Gilead Sciences, Inc. in 2015

Gilead Sciences may look cheap, but three of our top analysts believe these three other biotech stocks could have an even better 2015.

Does This Drug Offer Exelixis Inc. Investors Hope for the Future?

A potential approval of Exelixis' cobimetinib in 2015 could help restore investors' confidence -- but risk remains.

19 Lesser-Known Biotech Stocks With Robust Drug Pipelines

See More EXEL News...

EXEL's Top Competitors

EXEL $1.87 (-5.08%)
Current stock: EXEL
ILMN $195.19 (-2.41%)
Current stock: ILMN
TMO $125.21 (-2.15%)
Current stock: TMO
WAT $119.05 (-1.30%)
Current stock: WAT